MAM
LAB icon

Meeder Asset Management’s Standard BioTools LAB Stock Holding History

Meeder Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-303
Closed -$2K – 1727
2017
Q3 		$2K Hold
303
– – ﹤0.01% 1460
2017
Q2 		$1K Hold
303
– – ﹤0.01% 1525
2017
Q1 		$2K Sell
303
-305
-50% -$1.93K ﹤0.01% 1377
2016
Q4 		$4K Buy
+608
New +$3.82K ﹤0.01% 877

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's LAB Position: Q4 2017 in Review

Meeder Asset Management sold out of Standard BioTools (LAB) in Q4 2017, closing a stake of 303 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in LAB in Q4 2016 and held it in 4 quarters. The position peaked at $4K in Q4 2016. 81 funds tracked by Wall St. Rank hold LAB as of Q4 2017.

  • Meeder Asset Management reported no remaining Standard BioTools position as of Q4 2017 after selling out during the quarter.
  • Meeder Asset Management sold 303 Standard BioTools shares in Q4 2017, an estimated $2K.
  • Meeder Asset Management first reported a position in Standard BioTools in Q4 2016 and held it in 4 quarters.
  • Meeder Asset Management's Standard BioTools position peaked at $4K in Q4 2016.
  • 81 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2017.

Based on Meeder Asset Management's 13F filing for Q4 2017, filed 2 Feb 2018.